DOCSLIB.ORG

COVID-19 Vaccine: Critical Questions with Complicated Answers

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COVID-19 Vaccine: Critical Questions with Complicated Answers Review Biomol Ther 29(1), 1-10 (2021) COVID-19 Vaccine: Critical Questions with Complicated Answers Mohammad Faisal Haidere1,†, Zubair Ahmed Ratan2,3,†, Senjuti Nowroz4, Sojib Bin Zaman5, You-Jung Jung6, Hassan Hosseinzadeh2,* and Jae Youl Cho7,* 1Department of Soil, Water and Environment, University of Dhaka, Dhaka 1000, Bangladesh 2School of Health & Society, University of Wollongong, NSW 2500, Australia 3Department of Biomedical Engineering, Khulna University of Engineering and Technology, Khulna 9203, Bangladesh 4Department of Chemistry, University of Dhaka, Dhaka 1000, Bangladesh 5Department of Medicine, School of Clinical Sciences, Monash University, Victoria 3800, Australia 6Biological Resources Utilization Department, National Institute of Biological Resources, Incheon 22689, Republic of Korea 7Department of Integrative Biotechnology, and Biomedical Institute for Convergence at SKKU (BICS), Sungkyunkwan University, Suwon 16419, Republic of Korea Abstract COVID-19 has caused extensive human casualties with significant economic impacts around the globe, and has imposed new challenges on health systems worldwide. Over the past decade, SARS, Ebola, and Zika also led to significant concerns among the scientific community. Interestingly, the SARS and Zika epidemics ended before vaccine development; however, the scholarly com- munity and the pharmaceutical companies responded very quickly at that time. Similarly, when the genetic sequence of SARS- CoV-2 was revealed, global vaccine companies and scientists have stepped forward to develop a vaccine, triggering a race toward vaccine development that the whole world is relying on. Similarly, an effective and safe vaccine could play a pivotal role in eradi- cating COVID-19. However, few important questions regarding SARS-CoV-2 vaccine development are explored in this review. Key Words: COVID-19, Vaccine, Vaccine backfires, Vaccine safety INTRODUCTION vember 2002 in the Guangdong province of China. After that epidemic, China reported more than 8,000 cases of disease Humans have a long history of battling against the viruses. and 774 deaths with a case-fatality rate of 7%. A decade later The constant battle between viruses and scientists has been in 2012, Middle East respiratory syndrome CoV (MERS-CoV) recognized as a key driver of medical advances. In this series first emerged in Saudi Arabia, with a total of 2,494 laboratory- of battles, the latest one is the outbreak of a novel coronavi- confirmed cases and 858 deaths with a case-fatality ratio of rus, COVID-19, originating in the Wuhan region of China in 34.4% (Corman et al., 2018; Peeri et al., 2020). However, CO- late December 2019 (Ratan et al., 2020). COVID-19 has af- VID-19 has caused a pandemic that has compelled the global fected at least 216 countries, areas or territories around the economy to grind to a halt. A vaccine remains the best op- world. So far, there had been approximately 54 million 301 tion for restoring normal life and global economies. This has thousand 156 cases and one million 316 thousand 994 deaths triggered a vaccine development race. According to Mullard’s confirmed globally due to this deadly virus by November 16, report (Mullard, 2020), as of 11 November 2020, there were 2020 (World Health Organization, 2020). Prior to the emer- 259 COVID-19 vaccine projects going on around the world. Of gence of Severe Acute Respiratory Syndrome CoV-2 (SARS- those, there were 79 protein, 16 virus-like particle, 22 DNA, 33 CoV-2), there were six human CoVs (HCoVs), including that RNA, 36 non-replicating and 20 replicating viral vector, 15 in- which caused the SARS global outbreak that started in No- activated and four live-attenuated, and 35 other vaccines can- Open Access https://doi.org/10.4062/biomolther.2020.178 Received Oct 13, 2020 Revised Nov 26, 2020 Accepted Dec 2, 2020 Published Online Jan 1, 2021 This is an Open Access article distributed under the terms of the Creative Com- mons Attribution Non-Commercial License (http://creativecommons.org/licens- *Corresponding Authors es/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, E-mail: [email protected] (Cho JY), and reproduction in any medium, provided the original work is properly cited. [email protected] (Hosseinzadeh H) Tel: +82-31-290-7868 (Cho JY), +61-2-4221-5351 (Hosseinzadeh H) Fax: +82-31-290-7870 (Cho JY), +61-2-4221-5945 (Hosseinzadeh H) †The first two authors contributed equally to this work. Copyright © 2021 The Korean Society of Applied Pharmacology www.biomolther.org 1 Biomol Ther 29(1), 1-10 (2021) Fig. 1. State of the vaccine race for COVID-19. Figure 1: State of the vaccine race for COVID-19 didate in development pipeline. Among them, 204 were still in 1a/b) comprises two-thirds of the total viral genome (~30 kb) the preclinical stage; 11 candidates were reached phase III and encodes 16 non-structure proteins. This ORF 1a/b has clinical trial stage, and the remaining were in between these the genetic function to roll-out the viral replication that con- stages (Fig. 1) (London School of Hygiene and Tropical Medi- trols the production of cellular proteins and keeps evading cine, 2020). the immune system of the host. The remaining portion of the A vaccine introduces the structure and biological agents of genome codes for four basic structural proteins, including a specific virus to antigen-presenting cells of the host, which spike (S) glycoprotein, small envelope (E) protein, matrix (M) engulf it and pass portions of it to activate helper T (Th) cells. protein, and nucleocapsid (N) protein, and several other ac- The Th cells then trigger other immune responses i.e., acti- cessory proteins (Guo et al., 2020). The crucial part of SARS- vation of B cells and cytotoxic T (Tc) cells. B cells produce CoV-19 and COVID-19 infection begins when the S protein antibodies that can prevent the virus from infecting cells, while of this pathogen binds to angiotensin-converting enzyme 2 Tc cells recognize and kill cells that are infected with the virus, (ACE2), a cellular receptor of the host (Fig. 2A). After binding that help the surveillance cells of the body to track the virus for to the ACE2 receptor, the conformation shift in the S protein long periods (Fig. 2B). In principle, understanding the etiology, enables fusion of the viral envelope with the cell membrane epidemiology, pathogenesis and immunobiology of the infec- via the endosomal pathway. Then, the virus enters the cell tion is of the utmost importance for the development of vac- and releases its RNA. This RNA then goes through transcrip- cines (Zepp, 2010). Thus, a few simple questions, although tion, translation, and replication. In this production line, RNA complicated to answer, have arisen regarding the basic prin- is translated into replicase polyproteins pp1a and 1ab, and ciples of vaccines that need to be resolved with regard to CO- those are then severed by viral proteinase into small products. VID-19 vaccine development. Here, we aim to address those Polymerase by discontinuous transcription yields a sequence simple questions. of subgenomic mRNAs that are eventually transformed into specific viral proteins. Subsequently, in the endoplasmic retic- ulum and Golgi apparatus, viral proteins and genome RNA are STRUCTURE AND PATHOPHYSIOLOGY OF packaged into the virion and then transported through vesicles COVID-19 to be released from the cell (Shereen et al., 2020). SARS-CoV-2 is a β-coronavirus belonging to the Sarbe- covirus subgenus of the Coronaviridae family, and is envel- TYPES OF VACCINE oped with non-segmented positive-sense RNA virus (Zhu et al., 2020). In broad terms, the genome of this virus can be The Coalition for Epidemic Preparedness Innovations divided into two parts. The first open reading frame (ORF (CEPI), a multilateral and multinational stakeholders foun- https://doi.org/10.4062/biomolther.2020.178 2 19 Haidere et al. COVID-19 Vaccine and Important Questions Fig. 2. COVID-19 and the vaccine. (A) A simple representation of the COVID-19 infection mechanism in the body. (B) Basic principles of vaccines in generalized form. Figure 2: COVID-19 and the vaccine. A) A simple representation of the COVID-19 infection dation for the development of vaccine against infectious dis- voke all the requisite steps leading to immune system activa- eases,mecha informednism in in theSeptember body. 2020 B) Bthatasic the princip nine separateles of vaccition nines vivo in, andgene to rprovidealized a for non-virulent,m. harmless type of technological platforms are being used to make an effective a given agent capable of generating a strong and adequate vaccine against SARS-CoV-2 (Gopinathan et al., 2020). Sci- immune response tailored against specific viral attack (Moser entist around the world using both the classical and next-gen- and Leo, 2010). Thus, some questions arise regarding the de- eration platforms. The classical platforms are whole-inactivat- velopment of the vaccine (see Table 1 for current development ed virus, live-attenuated virus, protein subunit, and virus-like state of COVID-19 vaccines) that will be administered to bil- particles, and the next-generation platforms are nucleic acids lions of people at risk of COVID-19 infection. (RNA and DNA), viral vectors (non-replicating and replicating), recombinant protein, and antigen-presenting cells (Le et al., 2020; van Riel and de Wit, 2020). However, as of September WILL VACCINE STIMULATE THE IMMUNE 2020 reported by CEPI, most of the frontrunner vaccines in RESPONSE? clinical studies have emphasized on spike protein of corona- virus and its versions as the key antigen responsible for the As mentioned earlier, ACE2 is the route of SARS-CoV-2 in- infection of COVID-19. CEPI also pointed out that eleven can- fection. However, this receptor plays a vital role in both innate didate vaccine in clinical stage using adjuvant to improve the and adaptive immune responses by modulating the antigen immunogenicity (Le et al., 2020).
Load more

Recommended publications
  • February 17, 2021
    January 30 – February 17, 2021 This weekly science review is a snapshot of the new and emerging scientific evidence related to COVID-19 during the period specified. It is a review of important topics and articles, not a guide for policy or program implementation. The findings captured are subject to change as new information is made available. We welcome comments and feedback at [email protected]. In depth: Should second doses of COVID-19 vaccines be delayed? Main message: While the rollout of multiple vaccines has offered hope to control or end the COVID-19 pandemic, global vaccine demand will continue to outpace supply for the foreseeable future. To date, people in 130 countries have not yet received a single dose of COVID-19 vaccine. In countries where vaccination has begun, limited supplies of vaccine in combination with surges in cases and deaths have overwhelmed health care systems. Further, the emergence of more transmissible SARS-CoV-2 variants has led many to question existing vaccine rollout plans and propose alternative strategies. Some countries and experts have recommended delaying second doses of vaccine to maximize the number of people who receive at least one dose. This raises a critical question: What do we know about vaccines, especially the vaccines for COVID-19, that may allow flexibility in vaccine schedules? This is a complex question and there may not be a straightforward answer. Our knowledge is evolving rapidly as vaccine trials progress and rollout continues, and we must keep in mind that different approaches to vaccine scheduling may be appropriate in different settings.
    [Show full text]
  • (ACIP) General Best Guidance for Immunization
    8. Altered Immunocompetence Updates This section incorporates general content from the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host (1), to which CDC provided input in November 2011. The evidence supporting this guidance is based on expert opinion and arrived at by consensus. General Principles Altered immunocompetence, a term often used synonymously with immunosuppression, immunodeficiency, and immunocompromise, can be classified as primary or secondary. Primary immunodeficiencies generally are inherited and include conditions defined by an inherent absence or quantitative deficiency of cellular, humoral, or both components that provide immunity. Examples include congenital immunodeficiency diseases such as X- linked agammaglobulinemia, SCID, and chronic granulomatous disease. Secondary immunodeficiency is acquired and is defined by loss or qualitative deficiency in cellular or humoral immune components that occurs as a result of a disease process or its therapy. Examples of secondary immunodeficiency include HIV infection, hematopoietic malignancies, treatment with radiation, and treatment with immunosuppressive drugs. The degree to which immunosuppressive drugs cause clinically significant immunodeficiency generally is dose related and varies by drug. Primary and secondary immunodeficiencies might include a combination of deficits in both cellular and humoral immunity. Certain conditions like asplenia and chronic renal disease also can cause altered immunocompetence. Determination of altered immunocompetence is important to the vaccine provider because incidence or severity of some vaccine-preventable diseases is higher in persons with altered immunocompetence; therefore, certain vaccines (e.g., inactivated influenza vaccine, pneumococcal vaccines) are recommended specifically for persons with these diseases (2,3). Administration of live vaccines might need to be deferred until immune function has improved.
    [Show full text]
  • Candidate Rotavirus Vaccine Recommendations for Consideration by the WHO Strategic Advisory Group of Experts (SAGE) on Immunization
    Candidate rotavirus vaccine recommendations for consideration by the WHO Strategic Advisory Group of Experts (SAGE) on Immunization 1. Overall recommendation WHO strongly recommends the inclusion of rotavirus vaccination into the national immunization programmes of all regions of the world. In particular, countries where deaths among children due to diarrhoeal diseases account for ≥10% of under-5 mortality rate should prioritize the introduction of rotavirus vaccination. Countries where deaths among children due to diarrhoeal diseases account for <10% of under-5 mortality rate should also consider the introduction of rotavirus vaccination based on anticipated reduction in mortality and morbidity from diarrhoea, savings in health care costs, and the cost-effectiveness of vaccination. Justification: Rotavirus is a major cause of mortality in countries with high diarrhoeal disease mortality among children under five years of age. Every year, rotavirus gastroenteritis is estimated to cause approximately 527,000 (475,000-580,000) deaths globally among children <5 years old. Most of these deaths occur in developing countries and 90% of the rotavirus- associated fatalities occur in Africa and Asia alone. Globally, >2 million children are hospitalized each year for rotavirus infections. In a recent report of sentinel hospital-based rotavirus surveillance from 35 nations representing each of the six WHO regions between 2001 and 2008, an average of 40% (range= 34%-45%) of hospitalizations for diarrhea among children < 5 years old were attributable to rotavirus infection. 2. Detailed recommendation: Extrapolating efficacy data from a rotavirus vaccine study performed in one population to use of same rotavirus vaccine in other populations Efficacy/effectiveness data from a rotavirus vaccine study performed in a population from one of three under-5 mortality rate categories* can be extrapolated for use in populations in the same under-5 mortality rate category.
    [Show full text]
  • Rotavirus Vaccine: Questions and Answers for Health Care Providers
    Rotavirus Vaccine Questions and Answers for Health Care Providers In April 2014, Manitoba Health, Seniors and Active Living launched a publicly-funded Rotavirus Immunization Program for infants born on or after March 1, 2014. In 2018, Manitoba, along with the rest of Canada, switched from RotarixTM to RotaTeq®. As of May 15, 2021, Manitoba has switched back to Rotarix®, for use in its publicly-funded Rotavirus Immunization Program, for infants born on or after April 1, 2021. This document includes an updated list of questions and answers for your reference. 1. Why is there a Rotavirus Immunization Program in Manitoba? 2. Who qualifies for publicly-funded rotavirus vaccine? 3. Which rotavirus vaccine does Manitoba use? 4. Why does the vaccine series need to be completed before eight months of age? 5. How is Rotarix® packaged? 6. How are the oral tube and cap disposed of after use? 7. Should a spit-up dose of vaccine be repeated? 8. Are there any precautions that health care providers should take when administering the oral rotavirus vaccine? 9. Oral rotavirus vaccine contains sucrose in an amount expected to have an effect on immunization injection pain. When should Rotarix® be given in relation to other vaccines to elicit a reduction in pain? 10. How do I administer Rotarix®? 11. Is additional screening for potential contraindications required prior to administering rotavirus vaccine? 12. Can infants born to mothers on immunosuppressive medication be immunized? 13. Are there any issues related to circulating maternal antibodies interfering with the response to the live attenuated vaccine? 14. Are the two rotavirus vaccines, RotaTeq® and Rotarix™, interchangeable? 15.
    [Show full text]
  • Case Studies Controversies in Vaccination
    European Review, Vol. 21, No. S1, S56–S61 r 2013 Academia Europæa. The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution license ,http://creativecommons.org/licenses/by/3.0/.. doi:10.1017/S1062798713000227 Session 3 – Case Studies Controversies in Vaccination ROMAN PRYMULA University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. E-mail: [email protected] Infectious diseases still jeopardize human health and even lives. In spite of the variety of advanced treatment methods, prevention is considered to be the most effective way to fight infections, and vaccination, no doubt, is one of the most effective preventive measures in the history of mankind. The vaccine controversy is based on a dispute over morality, ethics, effectiveness, and/or safety. There is no 100% safe or effective vaccine; however, benefits clearly overweigh risks. Ironically, as the numbers of cases of vaccine- preventable infectious diseases are falling, the controversies relating to vaccine safety are growing. Vaccines are generally victims of their own success. Controversies can afflict the positive acceptance of immunization, decrease the coverage and uptake and finally threaten the health of children and adults. The advent of vaccination has proven to be one of the most effective preventive measures in the history of medicine. Vaccines play a significant role in the prevention of debili- tating and, in many cases, life-threatening infectious diseases. Vaccines also provide important benefits in terms of reducing or avoiding costs associated with illness, both direct and indirect. In spite of the absence of any kind of ideal global healthcare system and lack of resources, the World Health Organisation (WHO) and the United Nations Children’s Fund (UNICEF) were able, in 1974, to establish a major global project called the Expanded Programme on Immunization (EPI).
    [Show full text]
  • Pink Book Webinar Series: Rotavirus and Hepatitis a Slides
    Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Rotavirus and Hepatitis A Pink Book Webinar Series 2018 Mark Freedman, DVM, MPH Veterinary Medical Officer Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Rotavirus: Disease and Vaccine Rotavirus . First identified as a cause of diarrhea in 1973 . Most common cause of severe gastroenteritis in infants and young children . Nearly universal infection by age 5 years . Responsible for up to 500,000 diarrheal deaths each year worldwide Rotavirus . Two important outer shell proteins—VP7, or G-protein, and VP4, or P-protein define the serotype of the virus . From 1996–2005, five predominate strains in the U.S. (G1–G4, G9) accounted for 90% of the isolates . G1 strain accounts for 75% of infections . Very stable and may remain viable for weeks or months if not disinfected Rotavirus Immunity . Antibody against VP7 and VP4 probably important for protection • Cell-mediated immunity probably plays a role in recovery and immunity . First infection usually does not lead to permanent immunity . Reinfection can occur at any age . Subsequent infections generally less severe Rotavirus Clinical Features . Short incubation period . First infection after 3 months of age generally most severe . May be asymptomatic or result in severe, dehydrating diarrhea with fever and vomiting . Gastrointestinal symptoms generally resolve in 3–7 days Rotavirus Complications . Infection can lead to severe diarrhea, dehydration, electrolyte imbalance, and metabolic acidosis .
    [Show full text]
  • Detailed Review Paper on Rotavirus Vaccines
    Rotavirus Vaccines 17 March 2009 Detailed Review Paper on Rotavirus Vaccines To be presented to the WHO Strategic Advisory Group of Experts (SAGE) on Immunization, April 2009 Ad-hoc group of experts on rotavirus vaccines Chair : G. Peter Members: T. Aguado, Z. Bhutta, L. De Oliveira, K. Neuzil, U. Parashar, D. Steele WHO Secretariat: C. Mantel, S. Wang, G. Mayers, E. Derobert Rapporteur: D. Payne 1 Rotavirus Vaccines 17 March 2009 Table of Contents I. Rotavirus Epidemiology and Rationale for Vaccination 1. Disease burden 2. Rationale for vaccination as the primary preventive measure II. Rotavirus Vaccine Efficacy and Safety in Pivotal Pre-Licensure Trials Brief summary of rotavirus vaccines 1. Rotarix ® 2. RotaTeq ® III. Newly Available Data from Clinical Trials in Africa and Asia and Post-introduction Vaccine Effectiveness Evaluations in the Americas 1. South Africa and Malawi clinical trials (Rotarix ®) 2. Hong Kong, Taiwan, and Singapore clinical trials (Rotarix ®) 3. Nicaragua post-introduction vaccine effectiveness case- control study (RotaTeq ®) 4. El Salvador post-introduction vaccine effectiveness case- control study (Rotarix ®) 5. United States post-licensure impact evaluation studies 6. Status of other ongoing studies IV. Vaccine Safety, Co-Administration, and Special Populations 1. Vaccine safety 2. Co-administration with other vaccines, particularly OPV 3. HIV-infected populations 4. Breast-feeding and Pre-term Infants V. Vaccine Schedules and Age Restrictions VI. Vaccine Cost-effectiveness and Decision-Making Regarding Program Implementation 1. Cost-effectiveness and affordability 2. Decision-making regarding vaccine introduction VII. Vaccine Program Implementation and Vaccine Delivery Logistics VIII. Integration with Diarrheal Control and Other Health Interventions and Communication 1.
    [Show full text]
  • ADVISORY COMMISSION on CHILDHOOD VACCINES TABLE of CONTENTS December 8, 2017
    ADVISORY COMMISSION ON CHILDHOOD VACCINES TABLE OF CONTENTS December 8, 2017 TAB • ACCV Agenda 1 • ACCV Charter • ACCV Roster • 2017 Meeting Dates • Meeting Minutes 2 o Draft Minutes – September 8, 2017 • Vaccine Injury Compensation Trust Fund Statement 3 o Vaccine Injury Compensation Trust Fund Summary Sheet for the Period of 10/1/2016 – 9/30/2017 • VICP Data and Statistics 4 • Meeting Presentations & Updates 5 o Report from the Division of Injury Compensation Programs 5.1 o Report from the Department of Justice 5.2 o Petitions to Add Injuries to the Vaccine Injury Table Introduction 5.3 o Petition to Add Tics as an Injury to the Vaccine Injury Table 5.4 o Petition to Add Asthma as an Injury to the Vaccine Injury Table 5.5 5.6 o Petition to Add Pediatric Autoimmune Neuropsychiatric Syndrome (PANS), Pediatric Infection-Triggered Autoimmune Neuropsychiatric Disorders (PITANDS), and Pediatric Autoimmune Neuropsychiatric Disorders (PANDAS) as Injuries to the Vaccine Injury Table o Petition to Add Experimental Autoimmune Encephalomyelitis (EAE) and/or 5.7 Acute Demyelinating Encephalomyelitis (ADEM) as injuries to the Vaccine Injury Table 5.8 o Update on the Immunization Safety Office Vaccine Activities (CDC) o Update on the National Institute of Allergy and Infectious Diseases Vaccine 5.9 Activities (NIH) o Update on the Center for Biologics, Evaluation and Research Vaccine 5.10 Activities (FDA) 5.11 o Update from the National Vaccine Program Office • Program Related Articles 6 6.1 o Popular Science, “Why Are We So Bad At Producing The Right
    [Show full text]
  • (Pneumococcal Conjugate Vaccine) Schedule
    Changes to the infant pneumococcal conjugate vaccine schedule Information for healthcare practitioners Changes to the infant pneumococcal conjugate vaccine schedule About Public Health England Public Health England exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. We do this through world-leading science, research, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health and Social Care, and a distinct delivery organisation with operational autonomy. We provide government, local government, the NHS, Parliament, industry and the public with evidence-based professional, scientific and delivery expertise and support. Public Health England Wellington House 133-155 Waterloo Road London SE1 8UG Tel: 020 7654 8000 www.gov.uk/phe Twitter: @PHE_uk Facebook: www.facebook.com/PublicHealthEngland For queries relating to this document, please contact: [email protected] © Crown copyright 2019 You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. Published December 2019 PHE publications PHE supports the UN gateway number: 2019204 Sustainable Development Goals 2 Changes to the infant pneumococcal conjugate vaccine schedule Contents About
    [Show full text]
  • Vaccine Names and Abbreviations Vaccine Names and Abbreviations Many Vaccines Are Documented in an Abbreviation and Not by Their Full Name
    Vaccine Names and Abbreviations Vaccine Names and Abbreviations Many vaccines are documented in an abbreviation and not by their full name. This page is designed to assist you in interpreting both old and new immunization records such as the yellow California Immunization Record, the International Certificate of Vaccination (Military issued shot record) or the Mexican Immunization Card described in the shaded sections. Vaccine Abbreviation/Name What it Means Polio Oral Polio oral poliovirus vaccine (no longer used in U.S.) OPV Orimune Trivalent Polio TOPV Sabin oral poliovirus Inactivated Polio injectable poliovirus vaccine eIPV IPOL IPV Pentacel combination vaccine: DTaP/Hib/IPV Pediarix combination vaccine: diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b and inactivated poliovirus (DTaP/IPV/Hep B) DTP or DPT combination vaccine: diphtheria, tetanus, pertussis (no longer DTP Tri-Immunol available in U.S.) (Diphtheria, Tetanus, Pertussis) Triple combination vaccine: difteria, tétano, tos ferina (diphtheria, tetanus pertussis) DT combination vaccine: diphtheria and tetanus vaccine (infant vaccine without pertussis component used through age 6) DTaP combination vaccine: diphtheria, tetanus and acellular pertussis DTaP/Tdap Acel-Imune Certiva (Diphtheria, Tetanus, acellular Daptacel Pertussis) Infanrix Tripedia Tdap combination vaccine: tetanus, diphtheria, acellular pertussis Adacel (improved booster vaccine containing pertussis for adolescents Boostrix and adults) DTP-Hib combination vaccine: diphtheria, tetanus,
    [Show full text]
  • Scientific Consultation on Zika Virus Vaccine Development
    World Health Organization and National Institute of Allergy and Infectious Diseases, National Institutes of Health Scientific Consultation on Zika Virus Vaccine Development January 10–11, 2017 5601 Fishers Lane Rockville, Maryland Meeting Summary Tuesday, January 10, 2017 INTRODUCTION Anthony S. Fauci, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), United States The National Institute of Allergy and Infectious Diseases (NIAID) and the World Health Organization (WHO) convened the Scientific Consultation on Zika Virus Vaccine Development to discuss challenges and recent advances in the development of Zika virus (ZIKV) vaccines. The NIAID Director opened the meeting by stating that the recent spread of ZIKV mirrors that of other emerging arboviruses in the Americas in the past several years, including chikungunya, West Nile, and dengue. The NIAID research response to Zika builds on those experiences. A primary goal of this research is to develop medical countermeasures including diagnostics, therapeutics, and vaccines. Challenges specific to the development of a Zika vaccine include: the lack of adequate animal models; uncertainties in the epidemiology, which affect clinical trial site selection; the likelihood that the vaccine will need to induce sterilizing immunity to prevent congenital Zika syndrome (CZS); preexisting immunity to other flaviviruses in some regions; and potential specific risks such as Guillain-Barré syndrome (GBS) and the administration of live vaccines to pregnant women. Several Zika vaccine candidates are being developed with different development timelines and likely target populations. The planned timelines include large, well-controlled clinical trials to evaluate safety and efficacy, and if successful, subsequent licensure; should public health need and available safety and efficacy data justify deployment of vaccine before licensure, access through appropriate regulatory mechanisms could be considered.
    [Show full text]
  • HPV(HUMAN PAPILLOMAVIRUS)VACCINE Cervarix® W H a T Y O U N E E D T O K N O W
    STATE OF CONNECTICUT DEPARTMENT OF PUBLIC HEALTH IMMUNIZATION PROGRAM PLEASE COPY THIS FOR ALL HEALTH CARE PROVIDERS IN YOUR PRACTICE TO: All Users of State Supplied Vaccine FROM: Mick Bolduc Vaccines For Children (VFC) Coordinator DATE: April 20, 2010 SUBJECT: Update on Rotavirus Vaccine The primary purpose of this communication is to provide you with an update on Rotavirus vaccine. Rotavirus Vaccine The Food and Drug Administration will be convening a meeting of its Vaccines and Related Biological Products Advisory Committee on May 7th to discuss available data concerning Glaxo Smith Kline’s Rotarix brand rotavirus vaccine as well as make recommendations for future use of the product. Since any decision concerning Rotarix will not be made until that meeting, the Immunization Program will continue to make Merck’s RotaTeq brand rotavirus vaccine available throughout the month of May. All rotavirus orders in May will be filled with RotaTeq. Providers should order RotaTeq in the space labeled “Rotavirus (Rotarix)” on the current Vaccine Order Form. When reporting your doses administered data, you can report your RotaTeq doses in the “Rotavirus” space provided on the doses administered page. As a reminder RotaTeq is administered in a 3 doses series so children who have already received one dose of Rotarix should receive 2 additional doses of RotaTeq. New Vaccine Information Statements Enclosed are the latest Vaccine Information Statements for Pneumococcal Conjugate Vaccine (updated 4/16/10) and Human Papillomavirus Vaccine (updated 3/30/10). As a reminder all Vaccine Information Statements can be downloaded at www.cdc.gov/vaccines/pubs/vis/default.htm As always, if you have any questions please contact the State Immunization Program at (860) 509-7929.
    [Show full text]